NCT03409250View on ClinicalTrials.gov

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Choroidal NeovascularizationAge Related Macular Degeneration
Interventions
DRUG

Ranibizumab, Lucentis

Intravitreal injection with Lucentis (Ranibizumab)

Trial Locations (1)

4102

Vista Klinik, Binningen

All Listed Sponsors
lead

Vista Klinik

OTHER

NCT03409250 - SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia | Biotech Hunter | Biotech Hunter